Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis

被引：15

作者：

Bravenboer N. ^{[1
]}

Papapoulos S.E. ^{[3
]}

Holzmann P. ^{[2
]}

Hamdy N.A.T. ^{[3
]}

Netelenbos J.C. ^{[1
]}

Lips P. ^{[1
,4
]}

机构：

[1] Department of Endocrinology, Academic Hospital Vrije Universiteit, Amsterdam

[2] Department of Oral Cell Biology, Academic Center Dentistry, Amsterdam

[3] Department of Endocrinology, Academic Hospital Leiden, Leiden

[4] Department of Endocrinology, Academic Hospital Vrije Universiteit, 1007 MB Amsterdam

来源：

Osteoporosis International | 1999年 / 9卷 / 6期

关键词：

Histomorphometry; Osteoporosis; Pamidronate;

D O I：

10.1007/s001980050175

中图分类号：

学科分类号：

摘要：

The effect of pamidronate therapy on bone histology was studied in patients with osteoporosis with at least one vertebral fracture in a randomized, double-masked, placebo-controlled, multi-center trial. Patients received pamidronate 150 mg/day or placebo in addition to calcium 500 mg/day and vitamin D3 400 IU/day. Transiliac bone biopsies were obtained before and after 1 or 2 years of treatment. Of these, 23 pairs of biopsies obtained from 14 women and 9 men (mean age ± SD, 61.5 ± 10 years) were of sufficient quality for histomorphometry. Histomorphometry was performed on sections stained with Goldner's trichrome, using a drawing tube and a digitizer. Urinary hydroxyproline excretion decreased significantly (p < 0.005) following pamidronate treatment, indicating a decrease in bone resorption. Osteoid volume and osteoid surface also decreased significantly in the pamidronate group (p < 0.004 and p < 0.003 respectively), consistent with a secondary decrease in bone formation. Osteoid variables did not change in the placebo-treated patients. Cortical thickness, trabecular bone volume and trabecular thickness did not change after pamidronate or placebo treatment. Wall thickness, however, showed a borderline increase following pamidronate treatment. After pamidronate, eroded surface and mineral apposition rate did not change significantly in the placebo and pamidronate groups. Mineralizing surface and activation frequency showed a borderline decrease in the placebo and pamidronate groups. The decrease in mineralization lag time was of borderline significance in the pamidronate group, corroborating the absence of any negative effect on mineralization. In conclusion, pamidronate treatment led to a decrease in bone turnover and did not interfere with bone mineralization.

引用

页码：489 / 493

页数：4

共 18 条

[1]

Papapoulos S.E., Landman J.O., Bijvoet O.L., Et al., The use of bisphosphonates in the treatment of osteoporosis, Bone, 13, (1991)

[2]

Storm T., Thamsborg G., Steiniche T., Et al., Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis, N Engl J Med, 322, pp. 1265-1271, (1990)

[3]

Liberman U.A., Weiss S.R., Broll J., Et al., Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis, N Engl J Med, 333, pp. 1437-1443, (1995)

[4]

Ott S.M., Woodson G.C., Huffer W.E., Et al., Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis, J Clin Endocrin Metab, 78, pp. 968-972, (1994)

[5]

Storm T., Steiniche T., Thamsborg G., Melsen F., Changes in bone histomorphometry after longterm treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis, J Bone Miner Res, 8, pp. 199-208, (1993)

[6]

Bone H.G., Downs R.W., Tucci J.R., Harris S.T., Weinstein R.S., Licata A.A., Et al., For the osteoporosis study centers. Dose-response relationships for alendronate treatment in osteoporotic elderly women, J Clin Endocrinol Metab, 82, pp. 265-274, (1997)

[7]

Chavassieux P.M., Arlot M.E., Reda C., Wel L., Yates A.J., Meunier P.J., Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis, J Clin Invest, 100, pp. 1475-1480, (1997)

[8]

Reid I.R., Wattie D.J., Evans M.C., Gamble G.D., Stapleton J.P., Cornish J., Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis, J Clin Endocrinol Metab, 79, pp. 1595-1599, (1994)

[9]

Valkema R., Vismans F.-J.F.E., Papapoulos S.E., Pauwels E.K.J., Bijvoet O.L.M., Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD, Bone Miner, 5, pp. 183-192, (1989)

[10]

Teerlink T., Tavenier P., Netelenbos J.C., Selective determination of hydroxyproline in urine by high peformance liquid chromatography using precolumn derivatization, Clin Chim Acta, 183, pp. 309-316, (1989)

← 1 2 →